Tri-VyLibra^®

Product Features:

• Tri-VyLibra is estrogen/progestin combined oral contraceptive (COC) indicated for use by women to prevent pregnancy and for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy, have achieved menarche, and who desire an oral contraceptive for birth control

The most common adverse reactions associated with Tri-VyLibra include headache/migraine, breast issues (including breast pain, enlargement, and discharge), vaginal infection, abdominal/gastrointestinal pain, mood disorders (including mood alteration and depression), genital discharge, changes in weight (including weight increased or decreased).

Use of COCs increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes). The risk increases with age, particularly in women over 35 years of age who smoke.